Publications - Functional Cancer Genomics Lab
Relevant publications
- Pedrani M, Salfi G, Merler S, Testi I, Cani M, Turco F, Trevisi E, Tortola L, Treglia G, Di Tanna GL, Vogl U, Gillessen S, Theurillat JP and Pereira Mestre R. Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol (2024).
https://www.ncbi.nlm.nih.gov/pubmed/38704358. - Corpetti M, Muller C, Beltran H, de Bono J and Theurillat JP. Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes. Eur Urol (2023).
https://www.ncbi.nlm.nih.gov/pubmed/38104015. - Bolis M, Bossi D, Vallerga A, Ceserani V, Cavalli M, Rito Ld, Zoni E, Mosole S, Rinaldi A, Mestre RP, D'Antonio E, Ferrari M, Stoffel F, Jermini F, Sommer SG, Bubendorf L, Schraml P, Moch H, Spahn M, Thalmann G, Julio MK, Rubin M, Theurillat JP. Dynamic prostate cancer transcriptome analysis delineates the trajectory of disease progression. Nat Commun 2021, 12:7033. 10.1038/s41467-021-26840-5
- Nabais Sá MJ, El Tekle G, de Brouwer APM, Sawyer SL, del Gaudio D, Parker MJ, Kanani F, van den Boogaard MJH, van Gassen K, Van Allen MI, Wierenga K, Purcarin G, Elias ER, Begtrup A, Keller-Ramey J, Bernasocchi T, Wiel L, Gilissen C, Venselaar H, Pfundt F, Vissers LEL, Theurillat JP, de Vries BBA. De Novo Variants in SPOP Cause Two Clinically Distinct Neurodevelopmental Disorders. Am J Hum Genet 2020,106:405-411. (IF: 9.0) https://doi.org/10.1016/j.ajhg.2020.02.001
- Janouskova H°, El Tekle G°, Bellini E, Udeshi ND, Rinaldi A, Ulbricht D, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev R, Mutch DG, Carney ME, Cerchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter P, Carr SA, Garraway LA, Wild PJ, Theurillat JP. Cancer Type-Specific SPOP Mutants Alter BET Protein Levels and Inhibitor Responses. Nat Med 2017; 9: 1046-1054. 10.1038/nm.4372
- Groner AC, Tribolet-Hardy J, Bernasocchi T, Cato L, Melchers D, Houtman R, Cato ACB, Tschopp P, Gu L, Corsinotti A, Quing Z, Fankhauser C, Fritz C, Poyet C, Garraway LA, Wild PJ, Theurillat JP, Brown M. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell 2016; 29: 846-858. https://doi.org/10.1016/j.ccell.2016.04.012
